基于间充质干细胞的心脏组织工程在心肌梗死后心脏修复中的研究进展  

Research Update on Restoring Cardiac Function After Myocardial Infarction via Mesenchymal Stem Cell-based Cardiac Tissue Engineering

作　　者：卞伟康 邹紫莹 张子玥 王菲 张代民 BIAN Weikang;ZOU Ziying;ZHANG Ziyue;WANG Fei;ZHANG Daimin(Department of Cardiology,Sir Run Run Hospital,Nanjing Medical University,Nanjing 211112,China)

机构地区：[1]南京医科大学附属逸夫医院心内科,南京211112

出　　处：《中国循环杂志》2024年第9期931-936,共6页Chinese Circulation Journal

基　　金：国家自然科学基金(81970342,81370304);江苏省重点研发计划(BE2018611)。

摘　　要：心肌梗死会导致心肌细胞的永久丧失和心脏泵功能障碍,而受限于心肌细胞极其有限的自我更新潜能,心脏缺血损伤后的修复能力极其低下。间充质干细胞(MSC)是一种来源广泛、易分离提取和体外培养的干细胞,因其有益的旁分泌效应而被视为治疗心肌梗死的理想细胞来源。然而MSC及其衍生物在动物模型中呈现出的心脏保护效能并未完全转化为实际的临床获益。近年来,基于MSC的心脏组织工程已广泛应用于心脏再生医学,并在梗死心脏中展现出卓越的修复潜能。本文回顾总结应用组织工程学策略提高MSC及其衍生物心脏修复效能的研究进展,以期为探索能促使MSC疗效实现高效临床转化的潜在策略提供依据。Myocardial infarction can lead to permanent loss of cardiomyocytes and depressed pumping efficiency of the heart.Due to the extremely limited self-renewal potential of cardiomyocytes,the capability of cardiac repair after ischemic injury is extremely low.Mesenchymal stem cells,one of the widely sourced,easily isolated,extracted and cultured stem cells,are regarded as an ideal source of stem cells for the treatment of myocardial infarction owing to their beneficial paracrine effects.However,the cardioprotective efficacy of mesenchymal stem cells and their derivatives observed in animal models has not been fully translated into visible clinical benefits for patients with myocardial infarction.Recently,mesenchymal stem cellbased cardiac tissue engineering has been widely used in cardiac regenerative medicine and demonstrated excellent cardiac repair potential in infarcted hearts.This article reviews recent research progress on the application of tissue engineering strategies to improve the cardiac repair efficacy of mesenchymal stem cells and their derivatives,aiming to provide evidences for exploring potential strategies that can realize the efficient clinical benefits of mesenchymal stem cell-treatment.

关 键 词：间充质干细胞 心肌梗死 组织工程 心脏再生 旁分泌 

分 类 号：R54[医药卫生—心血管疾病]